Introduction: Who Should Undergo Diagnostics

Finding out whether someone has hyperchylomicronaemia involves careful attention to symptoms and specific testing. People who should consider diagnostic evaluation include those experiencing repeated episodes of severe stomach pain, particularly in the upper abdomen that may spread to the back. This pain often appears as colicky discomfort in infants, or may manifest as recurrent bouts of abdominal pain in children and adults.^[1]

Children who fail to grow and develop as expected, despite adequate nutrition, may need evaluation for this condition. Because hyperchylomicronaemia is an inherited disorder, it frequently shows up early in life, often during infancy or childhood, though some people don’t develop noticeable symptoms until adulthood. Approximately one quarter of people with this condition receive their diagnosis within the first year of life.^[8]

Anyone with a family history of this disorder should seek diagnostic testing, as the condition follows a pattern of autosomal recessive inheritance, which means you must inherit an altered gene from both parents to develop the disease. If someone in your family has been diagnosed with hyperchylomicronaemia, other family members may be carriers of the genetic mutation even if they don’t have symptoms.^[1]

Medical evaluation is particularly important when someone experiences inflammation of the pancreas, known as pancreatitis, without an obvious cause such as gallstones or alcohol consumption. The condition should also be considered when individuals develop yellow fatty deposits under the skin, called xanthomas, especially on the back, buttocks, feet, ankles, knees, and elbows. These skin changes appear in about half of all patients with hyperchylomicronaemia.^[3]

Women who experience their first symptoms during pregnancy or after starting estrogen-containing medications should also be evaluated. These situations can trigger the initial appearance of hyperchylomicronaemia symptoms in people who have the genetic mutations but haven’t previously shown signs of the disease.^[3]

Diagnostic Methods: How the Condition Is Identified

The diagnosis of hyperchylomicronaemia begins with recognizing the clinical picture and confirming it through specific laboratory tests. The process typically involves multiple steps, starting with a physical examination and progressing through increasingly specialized testing.

Clinical Signs and Symptoms

During a physical examination, healthcare providers look for specific signs that suggest hyperchylomicronaemia. They may find an enlarged liver and spleen, which occurs when these organs accumulate excess fat particles. The doctor may notice the characteristic yellow fatty deposits, or xanthomas, on the skin, which appear as raised, yellowish bumps. These are most commonly found on the back, buttocks, and around joints.^[5]

An eye examination may reveal a condition called lipemia retinalis, where the blood vessels in the back of the eye appear pale or creamy white instead of their normal red color. This happens because the blood contains so many fat particles that it changes appearance. The retina itself may also look pale. This finding is particularly suggestive of very high triglyceride levels.^[5]

Healthcare providers will take a detailed medical history, asking about episodes of abdominal pain, pancreatitis, family history of similar symptoms, and diet. They will also inquire about any medications being taken, as some drugs can worsen triglyceride levels in people who have the genetic predisposition for hyperchylomicronaemia.^[8]

Blood Tests: The Primary Diagnostic Tool

Blood testing forms the cornerstone of hyperchylomicronaemia diagnosis. The most important initial test measures triglyceride levels in the blood. Normal triglyceride levels are less than 150 milligrams per deciliter. In people with hyperchylomicronaemia, triglyceride levels are dramatically elevated, often exceeding 1,000 milligrams per deciliter, and can reach levels over 2,000 milligrams per deciliter or even higher.^[8]

A distinctive feature that can be observed even before formal laboratory analysis is the appearance of the blood sample itself. When blood is drawn from someone with severe hyperchylomicronaemia, the plasma portion appears milky or creamy rather than the normal clear yellow color. This milky appearance is caused by the massive accumulation of chylomicrons, the large fat-carrying particles that build up when the body cannot break them down properly.^[3]

When a blood sample is left to stand or is spun in a laboratory centrifuge, a creamy layer forms on top of the tube. This visual finding is highly characteristic of hyperchylomicronaemia and can provide an immediate clue to the diagnosis before detailed measurements are completed.^[3]

Importantly, people with hyperchylomicronaemia have severely elevated triglycerides even after fasting. Normally, chylomicrons should be cleared from the bloodstream within three to four hours after eating. However, in hyperchylomicronaemia, these particles persist in the circulation. Triglyceride levels may be ten times higher than normal, even when the person has not eaten for many hours.^[1]

Lipoprotein Lipase Activity Testing

A more specialized test can measure the activity of lipoprotein lipase, the enzyme that is deficient or non-functional in hyperchylomicronaemia. This test, called post-heparin lipoprotein lipase activity, involves giving a medication called heparin through a vein and then measuring the enzyme activity in blood samples taken afterward. In people with hyperchylomicronaemia, this test shows low or completely absent lipoprotein lipase activity.^[3]

The test can also measure the actual amount of lipoprotein lipase protein present in the blood, not just its activity. Some people may have normal amounts of the protein, but it doesn’t work properly due to genetic mutations. Others may produce very little or no lipoprotein lipase at all.^[3]

Ruling Out Secondary Causes

An important part of diagnosing hyperchylomicronaemia involves making sure that extremely high triglycerides are not caused by other medical conditions or medications. Several situations can cause severe triglyceride elevation in people who do not have the inherited form of the disease. Healthcare providers must exclude these secondary causes before confirming a diagnosis of primary hyperchylomicronaemia.^[3]

Conditions that can cause similar triglyceride elevations include poorly controlled diabetes, excessive alcohol consumption, certain kidney diseases, and thyroid disorders. Medications that can worsen triglycerides include estrogen therapy, some blood pressure medications, corticosteroids, certain antidepressants, and isotretinoin used for severe acne. If any of these factors are present, they must be addressed and controlled before concluding that someone has inherited hyperchylomicronaemia.^[3]

Genetic Testing

The definitive diagnosis of familial hyperchylomicronaemia is confirmed through genetic testing, which identifies mutations in the genes responsible for the condition. About 80 percent of cases result from inherited defects in both copies of the lipoprotein lipase gene. The remaining 20 percent involve mutations in other genes that are necessary for lipoprotein lipase to function properly. These include genes for proteins called apolipoprotein C-II, apolipoprotein A-V, glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1, and lipase maturation factor 1.^[1]

More than 220 different mutations in the lipoprotein lipase gene have been identified as causes of hyperchylomicronaemia. Genetic testing can pinpoint exactly which mutations a person carries. The test looks for either two copies of the same mutated gene or two different mutations, one inherited from each parent. This pattern is called homozygous or compound heterozygous mutation.^[3]

Genetic testing is particularly valuable for confirming the diagnosis when clinical features and blood tests strongly suggest hyperchylomicronaemia. It can also identify family members who are carriers of a single mutated gene. Carriers typically don’t have the disease themselves but may have mildly elevated triglycerides and can pass the mutation to their children.^[8]

However, access to genetic testing may be limited by cost and availability in some healthcare settings. Even when genetic testing cannot be performed, doctors can still make a clinical diagnosis based on symptoms, physical findings, extremely high triglyceride levels, absent or low lipoprotein lipase activity, and the exclusion of secondary causes.^[13]

Diagnostics for Clinical Trial Qualification

For people interested in participating in clinical trials for hyperchylomicronaemia, additional diagnostic criteria and tests may be required beyond those used for standard clinical diagnosis. Clinical trials often have strict eligibility requirements to ensure that participants truly have the condition being studied and that the results will be meaningful.

Strict Triglyceride Thresholds

Clinical trials typically establish specific triglyceride level thresholds that participants must meet. For hyperchylomicronaemia trials, this often means fasting triglyceride levels above 880 milligrams per deciliter measured on multiple occasions. Some trials may require even higher levels, such as above 1,000 or 1,500 milligrams per deciliter. The requirement for multiple measurements ensures that the elevation is persistent and not due to temporary factors.^[13]

Trial protocols may also specify that triglyceride levels must remain elevated despite the participant following a very low-fat diet and trying standard treatments such as medications called fibrates or omega-3 fatty acid supplements. This requirement helps identify people with true treatment-resistant disease who would benefit most from experimental therapies.^[9]

Genetic Confirmation Requirements

Many clinical trials for hyperchylomicronaemia require genetic testing to confirm that participants have mutations in one of the genes known to cause the condition. Trials may specifically look for participants with mutations in the lipoprotein lipase gene or may accept mutations in any of the several genes associated with familial hyperchylomicronaemia.^[13]

The genetic testing for clinical trials is often more comprehensive than what might be done in routine clinical care. Researchers want to be certain that participants have the monogenic form of hyperchylomicronaemia rather than other types of severe triglyceride elevation. Some trials may even sequence the entire gene or multiple genes to identify previously unknown mutations.

Documentation of Clinical History

Clinical trials typically require detailed documentation of symptoms and complications related to hyperchylomicronaemia. This may include medical records documenting episodes of pancreatitis, hospitalisations for abdominal pain, or evidence of other complications such as xanthomas or hepatosplenomegaly. Researchers may require participants to have experienced a certain number of pancreatitis episodes within a specific timeframe.^[13]

The age at which symptoms first appeared may also be important for trial qualification. Because familial hyperchylomicronaemia is present from birth, trials often look for participants who developed symptoms in childhood, adolescence, or early adulthood, rather than later in life when secondary causes of hypertriglyceridaemia are more common.

Exclusion of Secondary Factors

Clinical trials have strict criteria for excluding participants who have conditions or take medications that could explain high triglycerides through mechanisms other than genetic lipoprotein lipase deficiency. Potential participants undergo thorough screening to rule out poorly controlled diabetes, excessive alcohol use, kidney disease, thyroid problems, and use of triglyceride-raising medications. Trials may require participants to have stable control of any other medical conditions for a specified period before enrollment.^[13]

Baseline Laboratory Testing

Beyond triglyceride measurements, clinical trials usually require comprehensive baseline laboratory testing. This includes complete blood counts, liver function tests, kidney function tests, blood sugar measurements, and tests for inflammation markers. These baseline measurements help researchers understand each participant’s overall health status and monitor for any changes or side effects during the trial.

Some trials may also require baseline measurements of lipoprotein lipase activity or mass in post-heparin plasma to characterise the severity of enzyme deficiency. Additional specialised tests might measure levels of different types of lipoproteins in the blood or assess the function of related metabolic pathways.